ECSP14032516A - N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales - Google Patents
N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinalesInfo
- Publication number
- ECSP14032516A ECSP14032516A ECIEPI201432516A ECPI201432516A ECSP14032516A EC SP14032516 A ECSP14032516 A EC SP14032516A EC IEPI201432516 A ECIEPI201432516 A EC IEPI201432516A EC PI201432516 A ECPI201432516 A EC PI201432516A EC SP14032516 A ECSP14032516 A EC SP14032516A
- Authority
- EC
- Ecuador
- Prior art keywords
- quinolin
- hetero
- methyl
- production
- cyclohexil
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title abstract 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 title 1
- 239000003936 androgen receptor antagonist Substances 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- -1 quinolin-4-yloxy Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
La invención se relaciona con N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas, intermediarios y métodos para su producción, uso de las mismas para tratar y/o prevenir enfermedades y uso de las mismas para producir productos medicinales y uso de los mismos para tratar y/o prevenir enfermedades, en especial enfermedades hiperproliferativas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12004764 | 2012-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14032516A true ECSP14032516A (es) | 2015-12-31 |
Family
ID=48699019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201432516A ECSP14032516A (es) | 2012-06-26 | 2014-12-19 | N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9428460B2 (es) |
| EP (1) | EP2864291B1 (es) |
| JP (1) | JP6181172B2 (es) |
| KR (1) | KR20150023880A (es) |
| AP (1) | AP3919A (es) |
| AR (1) | AR091565A1 (es) |
| AU (1) | AU2013283543B2 (es) |
| BR (1) | BR112014032538A2 (es) |
| CA (1) | CA2877786C (es) |
| CL (1) | CL2014003443A1 (es) |
| CO (1) | CO7170167A2 (es) |
| CR (1) | CR20140593A (es) |
| CU (1) | CU20140144A7 (es) |
| CY (1) | CY1118412T1 (es) |
| DK (1) | DK2864291T3 (es) |
| DO (1) | DOP2014000295A (es) |
| EA (1) | EA028063B1 (es) |
| EC (1) | ECSP14032516A (es) |
| ES (1) | ES2609455T3 (es) |
| HR (1) | HRP20161745T1 (es) |
| HU (1) | HUE032306T2 (es) |
| IL (1) | IL236146B (es) |
| JO (1) | JO3342B1 (es) |
| LT (1) | LT2864291T (es) |
| MA (1) | MA37700B1 (es) |
| ME (1) | ME02590B (es) |
| MX (1) | MX2014016054A (es) |
| NZ (1) | NZ703100A (es) |
| PE (1) | PE20150154A1 (es) |
| PH (1) | PH12014502869A1 (es) |
| PL (1) | PL2864291T3 (es) |
| PT (1) | PT2864291T (es) |
| RS (1) | RS55500B1 (es) |
| SG (1) | SG11201408254UA (es) |
| SI (1) | SI2864291T1 (es) |
| TN (1) | TN2014000532A1 (es) |
| TW (1) | TWI600646B (es) |
| UA (1) | UA115447C2 (es) |
| UY (1) | UY34881A (es) |
| WO (1) | WO2014001247A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017513954A (ja) * | 2014-04-22 | 2017-06-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| EP3452451A4 (en) * | 2016-05-04 | 2019-11-13 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328821A (en) | 1991-12-12 | 1994-07-12 | Robyn Fisher | Cold and cryo-preservation methods for human tissue slices |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| WO2002000624A2 (en) | 2000-06-23 | 2002-01-03 | Eli Lilly And Company | Methods and compounds for inhibiting mrp1 |
| CA2454538A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| KR100863667B1 (ko) | 2002-09-11 | 2008-10-15 | 가부시끼가이샤 구레하 | 아민 화합물 및 그 용도 |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| EP1590334B1 (en) | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2005094251A2 (en) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3muscarinic acetylcholine receptor antagonists |
| SE0401342D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| WO2005117570A1 (en) | 2004-05-27 | 2005-12-15 | Jack Saffron | Feeding dish to prevent pest infestation |
| WO2006052722A1 (en) | 2004-11-09 | 2006-05-18 | Smithkline Beecham Corporation | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| US20060293341A1 (en) | 2005-06-23 | 2006-12-28 | Vrej Jubian | Alkyl sulfonamide derivatives |
| CN101378747A (zh) | 2006-02-06 | 2009-03-04 | 昭和电工株式会社 | 增白皮肤病制剂 |
| US20110053931A1 (en) | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2008064432A1 (en) | 2006-12-01 | 2008-06-05 | The University Of Sydney | Polycyclic molecular compounds |
| US8377949B2 (en) | 2007-08-16 | 2013-02-19 | Boehringer Ingelheim International Gmbh | Quinazolinedione chymase inhibitors |
| TWI469971B (zh) * | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| WO2009140549A1 (en) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| AU2009300328A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| KR20120051022A (ko) | 2009-07-21 | 2012-05-21 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리데 바이러스의억제제 |
| WO2011029782A1 (en) | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
-
2013
- 2013-06-24 EP EP13731325.0A patent/EP2864291B1/en active Active
- 2013-06-24 AP AP2014008141A patent/AP3919A/en active
- 2013-06-24 SG SG11201408254UA patent/SG11201408254UA/en unknown
- 2013-06-24 EA EA201500039A patent/EA028063B1/ru not_active IP Right Cessation
- 2013-06-24 MX MX2014016054A patent/MX2014016054A/es unknown
- 2013-06-24 JP JP2015519023A patent/JP6181172B2/ja not_active Expired - Fee Related
- 2013-06-24 LT LTEP13731325.0T patent/LT2864291T/lt unknown
- 2013-06-24 UA UAA201500561A patent/UA115447C2/uk unknown
- 2013-06-24 WO PCT/EP2013/063118 patent/WO2014001247A1/en not_active Ceased
- 2013-06-24 ME MEP-2016-292A patent/ME02590B/me unknown
- 2013-06-24 NZ NZ703100A patent/NZ703100A/en not_active IP Right Cessation
- 2013-06-24 HU HUE13731325A patent/HUE032306T2/en unknown
- 2013-06-24 DK DK13731325.0T patent/DK2864291T3/en active
- 2013-06-24 US US14/408,876 patent/US9428460B2/en not_active Expired - Fee Related
- 2013-06-24 SI SI201330440A patent/SI2864291T1/sl unknown
- 2013-06-24 BR BR112014032538A patent/BR112014032538A2/pt not_active Application Discontinuation
- 2013-06-24 PL PL13731325T patent/PL2864291T3/pl unknown
- 2013-06-24 JO JOP/2013/0192A patent/JO3342B1/ar active
- 2013-06-24 MA MA37700A patent/MA37700B1/fr unknown
- 2013-06-24 RS RS20161149A patent/RS55500B1/sr unknown
- 2013-06-24 AU AU2013283543A patent/AU2013283543B2/en not_active Ceased
- 2013-06-24 PE PE2014002495A patent/PE20150154A1/es active IP Right Grant
- 2013-06-24 ES ES13731325.0T patent/ES2609455T3/es active Active
- 2013-06-24 CA CA2877786A patent/CA2877786C/en not_active Expired - Fee Related
- 2013-06-24 KR KR20157001996A patent/KR20150023880A/ko not_active Ceased
- 2013-06-24 PT PT137313250T patent/PT2864291T/pt unknown
- 2013-06-24 HR HRP20161745TT patent/HRP20161745T1/hr unknown
- 2013-06-26 TW TW102122775A patent/TWI600646B/zh not_active IP Right Cessation
- 2013-06-26 UY UY0001034881A patent/UY34881A/es not_active Application Discontinuation
- 2013-06-26 AR ARP130102253 patent/AR091565A1/es unknown
-
2014
- 2014-12-09 IL IL236146A patent/IL236146B/en active IP Right Grant
- 2014-12-18 CR CR20140593A patent/CR20140593A/es unknown
- 2014-12-18 CL CL2014003443A patent/CL2014003443A1/es unknown
- 2014-12-18 CU CUP2014000144A patent/CU20140144A7/es unknown
- 2014-12-19 DO DO2014000295A patent/DOP2014000295A/es unknown
- 2014-12-19 EC ECIEPI201432516A patent/ECSP14032516A/es unknown
- 2014-12-19 CO CO14279115A patent/CO7170167A2/es unknown
- 2014-12-22 PH PH12014502869A patent/PH12014502869A1/en unknown
- 2014-12-25 TN TN2014000532A patent/TN2014000532A1/fr unknown
-
2016
- 2016-12-23 CY CY20161101343T patent/CY1118412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591087A1 (ru) | Новые производные бензимидазола в качестве антагонистов рецептора ep4 | |
| CR20150370A (es) | Compuestos antivirales | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| NI201500038A (es) | Piridinonas bicíclicas novedosas | |
| UY34603A (es) | Anticuerpos anti-asic-1 y usos de los mismos | |
| UY34660A (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| MX2015001051A (es) | Derivados de manosa, un proceso para su preparacion y sus usos como un farmaco. | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| UY34543A (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica. | |
| DOP2014000295A (es) | N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales | |
| CL2016001495A1 (es) | Espiro-oxazolonas. | |
| MX2015002514A (es) | Antagonistas de los receptores de quimiocina. | |
| UY34664A (es) | Derivados de piridona y piridazinona como antagonistas de mch-1r, composiciones farmacéuticas y sus usos | |
| UY34320A (es) | 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos. | |
| UY34703A (es) | Ciclobutilcarboxamidas, proceso para su preparación, composiciones pesticidas y composiciones farmacéuticas que las comprenden, y usos de las mismas como nematicidas | |
| TWD180406S (zh) | 拋棄式尿布 | |
| ES2421810R1 (es) | Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina |